Samsung’s venture activity is conducted through multiple arms, primarily Samsung Venture Investment Corporation and Samsung NEXT. Together, these entities invest globally across early-stage through pre-IPO companies, with substantial annual deployment and strong ties to one of the world’s largest electronics and consumer hardware ecosystems. Their value is both financial and deeply strategic.

Samsung has invested in neurotech-relevant companies such as Earable Neuroscience and NeuraLight, reflecting interest in sensor-driven brain health, wearables, and AI-enabled neurological monitoring. For founders, Samsung’s biggest differentiator is its hardware scale, sensor capability, and consumer health distribution potential. It is especially compelling for companies that could benefit from integration into wearables, audio platforms, mobile ecosystems, or global hardware supply chains.

Samsung invests globally, with major offices across Asia, the US, Europe, and Israel. For neurotech, it is particularly relevant to digital biomarkers, wearables, consumer neurotech, and sensing platforms rather than classical therapeutics. It is one of the strongest strategic corporates for founders building scalable neurotechnology with hardware or consumer-device components.